All Posts

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Originally published 2/3/23; last updated 3/29/23 Summary: Many exciting liver disease catalysts are coming in the first quarter of the...

Summary: The CYTK PDUFA for Omecamtiv Mecarbil is coming up on February 28 for heart failure with reduced ejection fraction (HErEF) The...

Summary: The CYTK PDUFA for Omecamtiv Mecarbil is coming up on February 28 for heart failure with reduced ejection fraction (HErEF) The Dec 13 AdComm vote was negative: committee voted 8-3 that Omecamtiv benefits do not outweigh risks Other exciting heart failure assets in 2023 include the ESPR presentation in March and two additional PDUFA decisions! CYTK's asset Omecamtiv Mecarbil has a PDUFA target action date of February 28, 2023 for the possible treatment of heart failur

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3...

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3 Sparsentan data readout in 2021 Other exciting kidney readouts in 2023 include PROK Ph2/3 data and CARA Ph3 data; and Ph3 KDNY data and Ph3 OMER data in IgAN. TVTX's asset Sparsentan has a PDUFA target action date of February 17, 2023 for the possible treatment of IgA Nephropathy. Sparsentan is a dual endothelin angiotensin receptor antagoni

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers such as prostate cancer and ovarian cancer Several smid-cap biopharmas are presenting data at ASCO-GU, including final results from BTAI We have also determined additional upcoming late stage trials in GU cancers in the next year   ASCO-GU 2023 starts February 16 and focuses on new and innovative findings and studies for the treatment of ge